The purpose of this study was to evaluate the feasibility, efficacy, safety, and GV of using combined injectable GLP1-RA and basal insulin therapy instead of twice-daily premixed insulin therapy in poorly controlled T2D patients. The gene discussed is GCG; the disease is type 2 diabetes mellitus.